Houston innovator aims to connect the dots between data science and phenomena

eyes to the sky

Houstonian Joe Schurman's latest venture PhenomAInon is aimed at tapping into AI and data analytics for for space domain awareness and threat detection. Photo via Getty Images

As artificial intelligence continues to expand its sphere of influence, Spring-based expert Joe Schurman is looking to take this technology to an out-of-this-world space.

With his background includes working with advising defense and aerospace organizations like NASA, Schurman's latest venture PhenomAInon is perfectly aligned with what he’s been working towards since 2019. The company aims to be a multi-tiered subscription service and application that will be the world’s first cloud native data and AI platform for phenomenon-based data analysis that can analyze data from any source for space domain awareness and threat detection, according to Schurman.

The platform aims to provide end-to-end data and AI analysis, publish insights, build community, and provide cloud, data, and software consulting. PhenomAInon deploys data and AI services alongside modern data and AI engineering, per the website, to surface insights to explorers, researchers, organizations, publications, and communities through advanced data and AI analysis. Schurman has worked with the U.S. government's task force for unidentified anomalous phenomenon — any perceived aerial phenomenon that cannot be immediately identified or explained — known as UAPTF. The tool will run sensitive information and then get back custom video analysis. The public version of the tool will give the public the option to view videos and cases, and form their own analysis.

“We are working together with multiple teams both public and private to continue to curate the data sets, clear documents for public review, and provide advanced analytics and AI capabilities never seen before to the public,” Schurman tells InnovationMap. “From a data and analytics perspective, we are applying machine learning and advanced analytics to find correlations and anomalies in the incident reports across multiple data sets.

"Some of these are public, some are private, and some we are clearing for public review," he continues. "The analytics will go far beyond incident reporting and showcase heat maps, correlative incident maps to key private and public sector facilities, and trends analysis never reported — e.g. incident reporting correlated with time, weather, FAA, and drone flight data, etc. We also have a new content analysis platform where users will be able to eventually run their own AI and ML analysis on their own videos.”

Schurman was first able to show this to the world in 2019, when as an adviser for To The Stars Academy of Arts and Science, or TTSA. He also appeared on History Channel’s “Unidentified: Inside America's UFO Investigation” to show the Pentagon’s former Advanced Aerospace Threat Identification Program head and TTSA Director of Special Programs Luis Elizondo how the AI platform could be helpful in tracking data related to Unidentified Aerial Phenomena.

Now, PhenomAInon's app is a work-in-progress. While it soft launched in May of 2022, Schurman says they have several data sets that are awaiting clearing from the U.S. government, as well as the content analysis tool in development to launch possibly by the summer. Schurman also hopes they will curate the largest library of incident videos, images, and audio recordings.

The subject of UAP continues to attract new discussions from government officials and industry professions across aerospace, academia, and more. In Houston, Rice University's Woodson Research Center and its humanities department host one of the largest archives of UAP and paranormal data, notes, and research that include documents from CIA programs on remote viewing.

Schurman says he's looking to provide even more data and information in this space.

“This phenomenon, it’s implications to multiple aspects of our lives and possible security threats, all come down to a data problem and the organizations that have been in place to-date just have not had the level of cloud, data and AI engineering capabilities we take for granted and have access to in the private sector,” says Schurman. “My goal is to bring this all together, starting with PhenomAInon.”

Eric Ingram and Sergio Gallucci of SCOUT are focused on creating data-driven solutions to space technology management to save companies billions and prevent space debris. Photos courtesy of SCOUT

Tech startup lands in Houston to help space support services take off

space tech

A Virginia-based space company startup focusing on developing small and inexpensive satellites is making an out-of-this-world entrance in the Houston commercial innovation space.

SCOUT has been selected as part of the 2020 MassChallange's Texas in Houston cohort, a zero-equity startup accelerator, in the commercial space track and is planning a demonstration mission with the Johnson Space Center in 2021.

The startup, founded in 2019 by Eric Ingram and joined shortly after by Sergio Gallucci. Both have years of experience in innovative research and development, leading teams across academia, government, and industry. Their data will help manufacturers and operators extend satellite lifetimes, avoid failing satellites, reducing up to a billion dollars in losses.

"If we want further operate in space and grow our space presence overall," Eric Ingram, CEO-and-founder tells InnovationMap. "We need to have a safe environment to expand that presence so any time you have unchecked failures and space debris is a problem. We want to help take some of the riskiness out of space operations by providing data that doesn't already exist."

SCOUT provides a wide array of new products based on data to produce small and inexpensive satellites to perform in-space inspections of large and expensive satellites. Their data and spaceflight autonomy software helps spacecraft detect, identify, and refine models for observed objects to gather information and enable autonomous operations.

The space startup's observation and comprehension capabilities creates data products for customers, such as Spacecraft Sensor Suites and Satellite Inspections. The former is a sensor suite under current development to enable a new way to monitor satellites in space while the latter consists of their small satellites that can enable on-demand and on-site inspections for space assets.

This, according to Ingram, is changing the paradigm of operational risk in space.

"If we are able to better understand how these satellites age over time and diagnose problems before they become catastrophic failures," says Ingram "We can prevent space debris from even happening. The more safety and responsibility in space, the better it is for everyone to increase their technology and investment in what is a very rapidly growing industry."

Lost satellites tend to happen often, resulting in about $300 million lost in hardware and around $40 million annual revenue gone. Spacecrafts in outer space can be part of many unpredictable interactions that can be difficult to trace including solar activity, thermal, mechanical wear, and outgassing.

SCOUT will focus the rest of the year in growing their company, despite the setbacks caused by the coronavirus. Their priority is to meet their fundraising and technical milestones while engaging in strategic partnerships with satellite industry players.

"The space industry is growing and is becoming a more realistic and viable avenue for business growth and investment," says Ingram. "Houston is a diverse city with innovation at every front and the effort that NASA is going through to aid the commercial space industry, combined with the startup accelerators that there is a lot of adjacent opportunities and overlap in capabilities."

The NASA-backed Translational Research Institute for Space Health is innovating the future of life in space. Libby Neder Photography

Houston-based organization tasked by NASA to take risks and innovate solutions in space health

HOUSTON INNOVATORS PODCAST EPISODE 14

For Dorit Donoviel, innovation means risk — and there's not a lot that's riskier than traveling to and living in outer space. As director of Houston-based TRISH — the Translational Research Institute for Space Health — Donoviel is tasked by NASA to take some risks in order to innovate.

"Everyone tosses the word 'innovation' around, but that means, to us, taking risks in science. Health care, in particular, is very risk averse, but the space industry is taking risks every single day when they put people in a rocket and hurl them into space," Donoviel says on this week's episode of the Houston Innovators Podcast. "If we're going to mars, for example, we are going to put people at risk.

"For us to take risks in order to reduce risk is a really amazing opportunity."

TRISH works hand in hand with NASA's Human Research Program to identify the program's biggest concerns, and then tap into professors, researchers, and scientists from Baylor College of Medicine, California Institute of Technology, the Massachusetts Institute for Technology, and other partners in order to innovate solutions.

Some of the issues TRISH is working to provide solutions for range from protecting from radiation exposure on the moon and mars to personal health care — astronauts have to be a doctor to themselves when they are on the space station.

"That's a totally new model for health care, so we have to solve all those problems and invest in them," Donoviel says.

In a lot of ways, TRISH connects the dots of modern space research, explains Donoviel. The organization taps into its researcher network, as well as into startups and companies with innovative technologies, in order to deliver the best space innovations to NASA.

Donoviel goes into more details on how TRISH interacts with entrepreneurs as well as what new technologies the organization has seen success with in the episode. Stream the podcast below, and subscribe wherever you get your podcasts.


Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

4 Houston health tech startups advancing medical innovation

meet the finalists

Houston has been driving medical innovation for decades. And thanks to leading hospitals, cutting-edge research and breakthrough technologies, the region’s healthcare ecosystem continues to improve how patients are diagnosed, treated and cared for.

The Health Tech Business category in our 2025 Houston Innovation Awards will honor an innovative startup within the health and medical technology sectors.

Four forward-thinking businesses have been named finalists for the 2026 award. This year's finalists, selected by our esteemed panel of judges, range from a startup developing miniaturized medical technologies for space to a company using AI to help develop cancer treatment plans.

Read more about these businesses, their innovative founders, and how they're shaping the future of health care below.. The 2026 winners will be announced on InnovationMap.com in mid-November.

Bairitone Health

Bairitone Health is bringing anatomy imaging for sleep apnea to the home environment. The company's platform maps users' anatomy during natural sleep using a facial patch to determine the root cause of airway obstruction. It then offers effective therapies for each patient.

The company was founded in 2022 in the Texas Medical Center's Biodesign program by CEO Meagan Pitcher, CTO Onur Kilic and chief medical officer Britt Cross. It was a member of Activate Houston's inaugural cohort and has participated in numerous accelerators and incubators. The company raised an oversubscribed seed round for $2.4 million earlier this year and received Breakthrough Device Designation from the Food and Drug Administration in April.

InformAI Inc.

InformAI Inc. develops fit-to-purpose AI solutions for the clinical setting. Its RadOncAI product recently received FDA 510(k) clearance. The product uses AI to create a first-pass radiation therapy dose plan for complex head and neck cancers in an effort to eliminate bottlenecks in radiation planning and ultimately cancer treatment. The company has also developed AI products for sinus disease detection and 3D organ reconstruction.

CEO Jim Havelka founded the company in 2017. It is participating in the Mayo Clinic Accelerate Platform. It has raised about $4 million in seed funding and has received numerous non-dilutive grants from the National Science Foundation, the National Institutes of Health and the Cancer Prevention and Research Institute of Texas. The company shared in its application that it plans to launch a Series A fundraising round and submit an FDA 510K application for its organ reconstruction product, Voluquant, by the end of 2026.

Prana Surgical

Prana Surgical is developing a minimally invasive surgical platform for small, hard-to-reach lung nodules that may be cancerous. The company's Prana System cleared U.S. Food and Drug Administration (FDA) approval earlier this year.

Prana Surgical was originally founded as Prana Thoracic in 2022. It has participated in numerous accelerators, including the Texas Medical Center Innovation Accelerator in 2023 and the IGNITE Health accelerator in 2022. It raised $6 million in Series A funding rounds in 2023 and 2024 , with a Series B currently ongoing. The company said in its application that it is currently moving into the next stage of clinical validation and revenue generation in the U.S., in addition to preparing its manufacturing and commercial infrastructure for broader use.

Skybound MedTech

Skybound MedTech develops technologies that aim to address the health risks of long-duration spaceflight. Its compact, miniaturized medical technologies can deliver complex therapies without a physician.

CEO Matthew Kuhn, who previously founded Taurus Vascular, founded Skybound last year. The company emerged from stealth in January after raising a $1.25 million Series A round. It plans to advance its lead dual-use platform into critical preclinical validation in November, the company shared in its application. It is currently raising a $25 million Series A round and is pursuing federal research partnerships with DARPA and ARPA-H.

Generation Park lands new facility to scale xeno-organ production

Organ innovation

Maryland-based United Therapeutics Corp. has opened a new 77,448-square-foot facility to manufacture xeno-organs in Northeast Houston’s growing biotech hub, Generation Park.

The new Houston location is United Therapeutics’ third Designated Pathogen-Free (DPF) site, named for transplant pioneers Dr. Bartley P. Griffith and Dr. Robert A. Montgomery. The company says the new facility will enable it to scale commercial production of its xeno-organs once they receive regulatory approval.

An existing DPF facility in Virginia is supporting clinical trials for the xeno-organs, and a third site in Minnesota will also focus on commercialization with the Houston site, according to the company.

Xeno-organs are organs taken from a non-human animal source and transplanted, implanted or infused into a human recipient.

Currently, United Therapeutics is advancing clinical trials to support a Biologics License Application with the U.S. Food and Drug Administration for its investigational-stage xenotransplantation, UKidney, UThymoKidney and UHeart products. The products all involve working with the genes from humans and pigs.

In 2025, Chron.com reported the company was working to construct an estimated $96 million facility to breed genetically engineered animals. Head of investor relations at United Therapeutics Dewey Steadman told the Houston Business Journal in 2025 that the pigs’ DNA will be edited. In November 2024, a 53-year-old woman in Alabama received a transplanted kidney from UKidney that had 10 gene edits. She had the transplant removed in April 2025, after her body rejected it.

The Dr. Bartley P. Griffith and Dr. Robert A. Montgomery Xenograft Production Facility requires a “strictly controlled, biosecure barrier environment, including air filtration, filtered water, filtered feed supplies, and state-of-the-art decontamination entryways,” according to the company. Being pathogen-free means it includes calibrated air and water conduits to support the transplantability of xenograft products and to prevent contamination. For energy considerations, the building also features solar arrays.

“With our third xenograft production facility now open and clinical trials underway, United Therapeutics is moving closer to its goal of providing transplantable organs to the people who need them,” Martine Rothblatt, chairperson and CEO of United Therapeutics, said in a news release. “It is fitting that this facility is named for Dr. Griffith and Dr. Montgomery, whose first-in-human surgeries turned xenotransplantation from a theoretical possibility into a clinical reality.”

The facility, which wrapped construction in August, is located at 11848 Common Dock Dr. in Generation Park, which will house manufacturing sites for pharmaceutical heavyweights Bristol Myers Squibb and Eli Lilly. Last fall, Eli Lilly tapped Generation Park for its $6.5 billion manufacturing plant, and Bristol Myers Squibb made a $2.3 billion investment in August to bring its state-of-the-art site to the master-planned commercial district.

Elon Musk's SpaceX reports profit as AI and satellite businesses booms

Booming Business

SpaceX reported a bigger quarterly profit than expected on Tuesday, October 20, as its satellite communications and artificial intelligence businesses boomed.

The company, run by Elon Musk, posted a profit for the three months through September 2026 of $4.4 billion, or 35 cents per share, reversing a year-ago loss and easily topping Wall Street's expectations. Revenue soared to $14.6 billion, up 161%.

On a conference call with analysts, Musk suggested a merger with his electric car company Tesla might be in the works, something that has been rumored for months. He said both companies formed “special committees” of independent directors to discuss the issue, though he played down the chances of an imminent deal.

“Some people out there assume that a SpaceX and Tesla merger is a certainty,” he said. “I think that would be overstating it.”

The AI business became SpaceX's largest by revenue in the third quarter, although the Starlink satellite service remains the biggest profit generator.

“They beat across all metrics and the Starlink business looks to be accelerating,” said Dan Ives, an analyst at Yorkville Ives. “This is just what (Wall) Street wanted.”

The stock rose 7.5% in after-hours trading.

Musk also told analysts that for next month's launch of its Starship rocket, SpaceX will attempt to grab both the booster and ship with mechanical arms upon return to base, a key step toward demonstrating it can reuse the massive spacecraft.

“The only way that we can extend consciousness beyond Earth on a sustained basis is with a fully reusable orbital launch vehicle,” Musk said, calling the attempt, if successful, “a massive technology milestone.”

SpaceX hopes to get Starship on a regular launch pattern in preparation for NASA's upcoming lunar missions.

The company already has huge contracts with the federal government, and House Democrats have called for investigations into those contracts and Musk’s work with the Department of Government Efficiency. Musk has spent $276 million since July in support of Republican candidates.

In a filing for its initial public offering in June, SpaceX warned that a change in control of Congress could have a “material and adverse impact on our growth and competitive position.”

Musk recently drew criticism from politicians in Washington after speeds for a military version of SpaceX's satellite communications service were slowed for Ukraine following President Donald Trump's deal to get more diesel oil from Russia amid a push to end the war. The Wall Street Journal reported Tuesday that it was Musk who ordered the slowdown, impeding Ukraine’s use of drones along the front. SpaceX did not immediately respond to an Associated Press request for comment on the Journal story.

Both Trump and Musk have denied responsibility for the slowdown.

As midterm elections near, Musk on Monday promised to give one share of SpaceX to “every kid in America” next year, though he provided no details on how the distribution would be carried out. With communities nationwide protesting the construction of large data centers and concerns about AI safety, AI companies are trying to build goodwill. Anthropic pledged to commit 5% of its shares to a new “public benefit” fund.

SpaceX shares have been under pressure over concerns that the company was spending too much on major projects to compete with rivals such as Anthropic. The company said capital expenditures totaled $19.6 billion last quarter, nearly triple the figure from a year earlier, and it forecast spending would grow to $35 billion to $40 billion in the current quarter.

Shares of SpaceX closed Tuesday at $147.79, down from a peak near $201 after its IPO, which made Musk the world’s first trillionaire at the time. But the share prices for SpaceX and Tesla have since dropped, reducing his net worth to $925 billion, according to Forbes magazine.

Tesla reports third-quarter financial results Wednesday. Last week, Tesla unveiled a new Roadster sports car that in some versions may include thrusters allowing it to briefly fly using SpaceX technology — though experts say anything usable for drivers is a long shot.

View All Listings